MOAB Trial: Optimal Atezolizumab for rGBM (Recurrent Glioblastoma)

MOAB Trial: Optimal Atezolizumab for rGBM (Recurrent Glioblastoma)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out if giving patients a drug called atezolizumab before and after surgery for recurrent glioblastoma can improve how their cancer responds.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Are diagnosed with glioblastoma (isocitrate dehydrogenase wildtype)
  • Have a recurrence after treatment with radiation and temozolomide
  • Plan to have surgery
For more information about who can join this study, please contact the study team at 919-684-5301.

What is Involved?

Description

If you join the study, you will:
  • Have a physical exam and other tests
  • Have magnetic resonance imaging (MRI) scans of the brain
  • Have blood draws
  • Get atezolizumab before surgery
  • Get atezolizumab after surgery

Study Details

Full Title

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

Principal Investigator

Mustafa
Khasraw

Protocol Number

PRO00113395

NCT ID

NCT06069726

Phase

N/A

Enrollment Status

Open to Enrollment